Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05977946 · ClinicalTrials.gov registry record · NA

Delivering Transcutaneous Auricular Neurostimulation to Regulate Platelet Activity in Healthy Human Subjects

A NA study of Hemostasis and Blood Biomarkers, sponsored by Spark Biomedical.

Completed
Registry status
NA
Development phase
25
Enrollment target
1
Study location

NCT05977946: Completed NA study of Hemostasis and Blood Biomarkers, sponsored by Spark Biomedical.

NCT05977946 is a NA study of Hemostasis and Blood Biomarkers that has completed, run by Spark Biomedical. The registered enrollment target is 25 participants, below the 394-participant average among 7 other Hemostasis trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05977946, a NA study of Hemostasis and Blood Biomarkers, has completed, sponsored by Spark Biomedical.

COMPLETED
Registry status
NA
Development phase
25 participants
Enrollment target
1
Study location

Study Summary

This study is designed as a randomized, double-blind, sham-controlled, single-center research study in which healthy adults will be randomized 1:1 into one of two experimental groups, to receive transcutaneous auricular vagus nerve stimulation (taVNS) targeting either the auricular branch of the vagus nerve (ABVN) or tAN, which targets the ABVN and the auriculotemporal nerve (ATN): 1. Group 1: Sham taVNS followed by active taVNS 2. Group 2: Sham tAN followed by active tAN Participants will receive 30 minutes of sham stimulation (taVNS or tAN), followed by active stimulation (taVNS or tAN). Blood biomarkers (local and systemic) will be measured before and at several timepoints after stimulation to measure the molecular and cellular effects of the device.

Primary Outcome

Mean TAT levels in shed blood after active stimulation versus sham stimulation within each group

Interventions

  • DEVICE Volta System

Study Locations (1)

New York

  • The Feinstein Institutes for Medical Research - Manhasset

Trial Details

FieldValue
Enrollment Target 25 participants
Start Date 2023-10-31
Est. Completion 2024-08-06
Phase NA
Spark Biomedical

13 total trials

What the finished NCT05977946 record still lists

NCT05977946 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 394-participant average among 7 other Hemostasis trials with a reported enrollment target (94% lower).

The record links to 2 conditions, with Hemostasis appearing as the primary indexed condition, and to 1 intervention - of which Volta System is the first listed.

NCT05977946 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT05977946 about?

NCT05977946 is a clinical study titled "Delivering Transcutaneous Auricular Neurostimulation to Regulate Platelet Activity in Healthy Human Subjects". This study is designed as a randomized, double-blind, sham-controlled, single-center research study in which healthy adults will be randomized 1:1 into one of two experimental groups, to receive transcutaneous auricular vagus nerve stimulation (taVNS) targeting either the auricular branch of the vag...

What is the current status of trial NCT05977946?

This trial is currently completed. It is a NA study. The enrollment target is 25 participants. The study started on 2023-10-31. Estimated completion is 2024-08-06.

What conditions does trial NCT05977946 study?

This clinical trial studies the following conditions: Hemostasis, Blood Biomarkers.

What interventions are being tested in trial NCT05977946?

The interventions under investigation include: Volta System (DEVICE).

Who is sponsoring clinical trial NCT05977946?

This trial is sponsored by Spark Biomedical, which has 13 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05977946 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Hemostasis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01166854 · 25 participants

    Characterization of Familial Myopathy and Paget Disease of Bone

  • NCT01913106 · 25 participants · Phase 1

    HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer

  • NCT02138669 · 25 participants · NA

    Intacs Prescription Inserts for Keratoconus Patients

  • NCT02174549 · 25 participants · Phase 1

    Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05977946, the US trial registry maintained by the National Library of Medicine. NCT05977946 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.